Takeda Kicks Off Effort On Globulin, Other COVID-19 Therapies
But China Plasma Collections Challenging
Executive Summary
Japan's largest pharma firm has joined the global fray to develop potential therapies for the spreading coronavirus outbreak, focusing initially on its plasma products expertise. But this approach has had some challenges in China.
You may also be interested in...
Takeda Vaccines Head: Peer Review Process For COVID-19 Vaccines Must Be 'Very Open'
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.
Coronavirus Update: EU Regulator Skeptical On Vaccine This Year, Takeda Prepares Hyperimmune Alliance
EMA leader doesn't share Oxford's optimism, Takeda-led alliance forges ahead with plasma-derived therapy plans, Indian pharma firm Cadila gets into testing kits.
Takeda Forecasts Tripling In Reported Op Profit Despite Virus Uncertainties
While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.